Thomas G. Todaro

Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction

Christopher B. Granger, Kenneth W. Mahaffey, W. Douglas Weaver et al. · Circulation · 2003 · 320 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass

Edward D. Verrier, Stanton K. Shernan, Kenneth M. Taylor et al. · JAMA · 2004 · 192 citations

Medicine, Pharmacology, Surgery +11

Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study

Abhinav Goyal, Kenneth W. Mahaffey, Jyotsna Garg et al. · European Heart Journal · 2006 · 188 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction

Kenneth W. Mahaffey, Christopher B. Granger, José Carlos Nicolau et al. · Circulation · 2003 · 176 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

Christopher E. Buller, Yuling Fu, Kenneth W. Mahaffey et al. · Circulation · 2008 · 148 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16